儿童癌症口腔黏膜炎评估量表的验证
Validation of the oral mucositis assessment scale in pediatric cancer.
作者信息
Sung Lillian, Tomlinson George A, Greenberg Mark L, Koren Gideon, Judd Peter, Ota Sylvia, Feldman Brian M
机构信息
Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
出版信息
Pediatr Blood Cancer. 2007 Aug;49(2):149-53. doi: 10.1002/pbc.20863.
BACKGROUND
Our objective was to examine the construct validity of the Oral Mucositis Assessment Scale (OMAS) in children receiving doxorubicin chemotherapy.
METHODS
Children between 6 and 18 years of age with cancer receiving doxorubicin-containing chemotherapy were included. OMAS was measured on days 7, 10, 14, and 17 after chemotherapy. Other measures of mucositis obtained concurrent with OMAS were the World Health Organization (WHO) mucositis scale and pain visual analogue scale (VAS). We also recorded analgesia administration.
RESULTS
Sixteen children were studied for 45 post-chemotherapy cycles and 156 OMAS assessments were performed. OMAS was moderately correlated with WHO scores (r = 0.56; P = 0.0006) whereas correlation with the pain VAS was fair (r = 0.37; P = 0.002). OMAS also had fair correlation with the number of doses of topical analgesia (r = 0.43; P = 0.001) and with the cumulative dose of opioid analgesia (r = 0.38; P = 0.003).
CONCLUSIONS
The OMAS is valid for use in mucositis clinical trials for children at least 6 years of age.
背景
我们的目的是检验口腔黏膜炎评估量表（OMAS）在接受多柔比星化疗的儿童中的结构效度。
方法
纳入6至18岁接受含多柔比星化疗的癌症患儿。在化疗后第7、10、14和17天测量OMAS。与OMAS同时获得的其他黏膜炎测量指标为世界卫生组织（WHO）黏膜炎量表和疼痛视觉模拟量表（VAS）。我们还记录了镇痛药物的使用情况。
结果
对16名儿童进行了45个化疗后周期的研究，共进行了156次OMAS评估。OMAS与WHO评分中度相关（r = 0.56；P = 0.0006），而与疼痛VAS的相关性一般（r = 0.37；P = 0.002）。OMAS与局部镇痛药物剂量数（r = 0.43；P = 0.001）以及阿片类镇痛药物累积剂量（r = 0.38；P = 0.003）也具有一般相关性。
结论
OMAS可有效用于至少6岁儿童的黏膜炎临床试验。
Zotero 插件